Law360, New York (May 28, 2014, 1:25 PM EDT) -- Boehringer Ingelheim International GmbH has agreed to pay roughly $650 million to settle claims in multidistrict litigation that its blood thinner Pradaxa caused serious injuries including severe bleeding, the German drugmaker said Wednesday.
The settlement resolves state and federal cases in the U.S., according to Boehringer's statement, which said that the U.S. Food and Drug Administration has reaffirmed the drug's positive benefit-risk profile. The drugmaker said that it expects the settlement will resolve roughly 4,000 claims over the drug.
"Time and again the benefits and safety of Pradaxa have been confirmed in many clinical trials and in real-world data analyses," Boehringer...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!